Spastic and myocloni in a childhood neurodegenerative disease - New therapeutic options

Neuroendocrinology Letters

Volumn 23, Issue 5-6, 2002, Pages 387-390

  Lorenz, Ruediger ^a  

^a NONE   (Germany)

Author keywords

Dronabinol; Epilepsy; Jansky bielschowsky; Marinol; Myoclonus; NCL; Piracetam; Spastic; THC; Zonisamide

Indexed keywords

BACLOFEN; CLOBAZAM; CLONAZEPAM; DOPA; DRONABINOL; MELATONIN; OXCARBAZEPINE; PETHIDINE; PIRACETAM; PRIMIDONE; TETRAZEPAM; VALPROIC ACID; ZONISAMIDE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIOXIDANT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; ISOXAZOLE DERIVATIVE; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; TETRAHYDROCANNABINOL;

ARTICLE; AUTOSOMAL RECESSIVE INHERITANCE; BEHAVIOR DISORDER; CASE REPORT; CHILD NUTRITION; CONSANGUINEOUS MARRIAGE; DEGENERATIVE DISEASE; DRUG DISTRIBUTION; DRUG EFFICACY; ELECTROENCEPHALOGRAM; HUMAN; MALE; MUSCLE BIOPSY; MYOCLONUS; NEURONAL CEROID LIPOFUSCINOSIS; OPTIC NERVE ATROPHY; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PRESCHOOL CHILD; SEIZURE; SPASTICITY; SPEECH DEVELOPMENT; TREATMENT INDICATION; CONSANGUINITY; DISEASE COURSE; ELECTROENCEPHALOGRAPHY; PALLIATIVE THERAPY; PATHOLOGY; SKELETAL MUSCLE; TREATMENT OUTCOME;

ANALGESICS, NON-NARCOTIC; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; ANTIOXIDANTS; BENZODIAZEPINES; CHILD, PRESCHOOL; CONSANGUINITY; DISEASE PROGRESSION; ELECTROENCEPHALOGRAPHY; HUMANS; ISOXAZOLES; MALE; MELATONIN; MUSCLE SPASTICITY; MUSCLE, SKELETAL; MYOCLONUS; NEURONAL CEROID-LIPOFUSCINOSES; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; PALLIATIVE CARE; PIRACETAM; SEIZURES; TETRAHYDROCANNABINOL; TREATMENT OUTCOME;

EID: 0036781646     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Menkes JH. Sarnat HB. Child Neurology. Philadelphia, Baltimore, New York, London, Buenos Aires, Hong Kong, Sydney, Tokyo: Lippincott Williams and Wilkins; 2000.
2. Philippart M, da Silva E, Chugani HT. The value of positon emission tomography in the diagnosis and monitoring of late infantile and juvenile lipopigment storage disorders (so-called Batten or neuronal ceroid tipofuscinoses). Neuropediatrics 1997; 28:74-76.
3. Shibasaki, H Yamashita Y, Neshige R, Tobimatsu S, Fukui R. Pathogenesis of giant somatosensory evoked potentials in progessive myoclonic epilepsy. Brain 1985; 108:225-240.
4. Uthman BM, Reichl A. Progressive myoclonic epilepsies. Curr. Treat Options Neurol 2002; 4:3-17.
5. Kleiber D, Kovar KA, Brandt C. Auswirkungen des Cannabiskonsums: eine Expertise zur parmakologischen und psychosozialen Komponente. Wissenschaftliche Verlags-Gesellschaft 1988.
6. Gardner EL, Lowinson JH. Marijuana's interaction with brain reward systems. Pharmacology, Biochemistry and Behaviour 1991; 40:571-580.
7. Müller-Vahl KR, Kolbe H, Schneider U, Emrich HM. Cannabis in movement disorders. Forschende Komplementärmedizin 1999, 3:23-27.
8. Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG. Cannabis-induced dopamine release: an in vivo SPECT study. Psychiatry Research 2001; 107:173-177.
9. Perez-Reyes M, Lipton MA, Timmons MC, Wall ME, Brine DR, David. KH. Pharmacology of orally administered delta 9-THC. Clinical Pharmacology and Therapeutics 1972; 14:48-55.
10. Gordon E, Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 2001; 42:1266-1272.
11. Robson R. Therapeutic aspects of cannabis and cannabinoids. British Journal of Psychiatry, 2001; 178:107-115.
12. Therapeutic uses of cannabis. British Medical Association, Harwood Academic Publishers 1997.
13. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, Sonvito WL, Lander N, Mechoulam R. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980; 21:175-185.
14. Zschocke S. Klinische Elektroenzephalographie. Springer; 2002. S. 513.
15. Perez-Reyes M, Wingfield M. Cannabidiol and etectroencephalographic epileptic activity. JAMA 1974; 230:1635.
16. van der Stelt M, Veldhuis WB, Bar PR, Veldink GA, Vliegenthart JF, Nicolay K. Neuroprotection by delta 9-THC, the main active compound in marijuana, against ouabain-induced in vivo exitotoxicity. Journal of Neuroscience 2001; 21 (17):6475-6479.
17. Hampson AJ, Grimaldi M, Lolic M, Wink D, Rosenthal R, Axelrod J. Neuroprotective antioxidants from marijuana. Annals of the New York Academy of Sciences 2000; 899:274-282.
18. Friedmann H, Klein TW, Newton C, Daaka Y. Marijuana, receptors and immunomodutation. Advances in Experimental Medicine and Biology 1995; 373:103-113.
19. Lorenz R. Letter to the editor. Neuroendocrinology Letters 2001; 22:330-331.
20. Lorenz R. Cytokines and epilepsy. A clinical study. Neuroendocrinology Letters 2002; 23:10-12.
21. Obeso JA, Artieda J, Quinn N et al Piracetam in the treatment of different types of myoclonus. Clin. Neuropharmacol 1998; 11:529-536.
22. Nicholson CD. Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology 1990; 101:147-159.
23. Donma MM. Clinical efficacy of piracetam in treatment of breath-holding spells. Pediatr Neurol 1998; 18:41-45.
24. Obeso JA, Artieda J, Luquin MR et al. Antimyoclonic action of piracetam. Clin. Neuropharmacol 1986; 9:58-64.
25. Bourrin JC, Chopard JL, Lassauge F, Boillot A, Dintroz M, Rousselot JP. Syndrome de Lance et Adams. Rapport d'une observation. Evolution favorable sous traitement. Fait Clinique, Lyon Médical 1982; 247 (2):39-43.
26. Yanai S, Hanai T, Narazaki O. Treatment of infantile spasms with zonisamide. Brain Development 1999; 21:157-161.
27. Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, Lamotrigine and zonisamide. Epilepsy Res 1998; 29:147-154.
28. Shimizu T, Yamashita Y, Satoi M et al. Heat stroke-like episode in a child caused by zonisamide. Brain Dev 1997; 19:366-368.
29. Brown P. Myoclonus. CNS Drugs 1995; 1:22-29.